Proxy Votes Now

Home › Funds › Global X › Global X HealthTech ETF

Global X HealthTech ETF (HEAL) proxy voting record 2025-2026

Fund family: Global X · Filed by Global X Funds (CIK 1432353) · SEC series S000069056

Ticker: HEAL (C000220776)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 352 with, 1 against, 2 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 1 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Global X as a whole

The same two figures as Global X’s manager page (125,623 ballot items across 92 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGlobal XItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)73.6%32991.0%107,427
Backed environmental and social shareholder proposals at US companiesn/a021.0%2,383

Where this fund voted differently from most Global X funds

Each ballot item this fund voted is set against the votes of the other Global X funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Global X funds on 14 items (19.7% of the 71 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Global X fundsMgmtResult
GE HealthCare Technologies Inc.2026-05-07Election of Directors: Kevin A. LoboAgainstFOR — 15 of 15 Global X fundsAgainstPassed (calculated), 91.2% support
DexCom, Inc.2026-05-27To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.AgainstFOR — 17 of 18 Global X fundsAgainstApproved, 88.3% support
DexCom, Inc.2026-05-27To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Dr. Euan AshleyAgainstFOR — 15 of 16 Global X fundsAgainst—
DexCom, Inc.2026-05-27To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Richard CollinsAgainstFOR — 15 of 16 Global X fundsAgainst—
DexCom, Inc.2026-05-27To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Steven AltmanAgainstFOR — 15 of 16 Global X fundsAgainstElected, 95.1% support
Insulet Corporation2026-05-20To approve, on a non-binding, advisory basis, the compensation of certain executive officers.AgainstFOR — 12 of 13 Global X fundsAgainstPassed (calculated), 92.0% support
Insulet Corporation2026-05-20Elect TImothy C. StonesiferWithholdFOR — 10 of 11 Global X fundsAgainst—
ResMed Inc.2025-11-19Ratify our selection of KPMG LLP as our Independent registered public accounting firm for the fiscal year ending June 30, 2026.AgainstFOR — 9 of 10 Global X fundsAgainst—
IQVIA Holdings Inc.2026-04-23Election of Directors: James A. FasanoAgainstFOR — 8 of 9 Global X fundsAgainst—
IQVIA Holdings Inc.2026-04-23Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2026.AgainstFOR — 8 of 9 Global X fundsAgainstApproved, 90.9% support
ResMed Inc.2025-11-19Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Christopher DelOreficeAgainstFOR — 8 of 10 Global X fundsAgainst—
ResMed Inc.2025-11-19Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Desney TanAgainstFOR — 8 of 10 Global X fundsAgainst—
ResMed Inc.2025-11-19Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Karen DrexlerAgainstFOR — 8 of 10 Global X fundsAgainst—
ResMed Inc.2025-11-19Election of director to serve until our 2026 annual meeting and until their successors are elected and qualified. The nominee for election as director at the 2025 annual meeting is: Ronald TaylorAgainstFOR — 8 of 10 Global X fundsAgainst—

Download all 14 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 77.2% of this fund’s 355 such votes could be given a sector; the other 81 (22.8%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care20610.5%
Technology3900.0%
Consumer Discretionary2900.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2190
Audit-related380
Say-on-Pay310
Compensation260
Corporate Governance261
Capital Structure160
Extraordinary Transactions20
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
IQVIA Holdings Inc.April 23, 2026$2M131
ResMed Inc.November 19, 2025$2M150
GE HealthCare Technologies Inc.May 7, 2026$2M100
DexCom, Inc.May 27, 2026$2M140
Oscar Health, Inc.June 4, 2026$2M100
Intuitive Surgical, Inc.April 30, 2026$1M130
Veeva Systems Inc.June 17, 2026$1M100
Waystar Holding Corp.June 1, 2026$939,21160

Notable votes against management

MeetingCompanyProposalFundMgmt
April 23, 2026IQVIA Holdings Inc.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalForAgainst

Search this fund’s votes by company

359 ballot items at 40 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Global X HealthTech ETF (HEAL) voted at 40 shareholder meetings of 39 companies, on 359 ballot items in all. Where management made a recommendation, the fund followed it on 99.2% of the items and voted against it 1 time. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 1 shareholder proposal. It voted FOR the board's own proposals less often than Global X's funds as a whole (73.6% against 91.0%). It voted differently from most Global X funds on 14 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Global X’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.